Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.30 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30867713 | 0.94 | MAP4K4 (0.31) | MAP4K4GPR119LMNANPSR1CYP1A2 | |
| SCHEMBL30867692 | 0.81 | GRM1 (0.45) | — | |
| SCHEMBL30867776 | 0.81 | CHRNA7 (0.31) | GPR119 | |
| SCHEMBL30867758 | 0.75 | GPR119 (0.38) | MAP4K4GPR119LMNANPSR1HDAC1 | |
| SCHEMBL30867920 | 0.72 | GPR119 (0.43) | GPR119LMNANPSR1 | |
| SCHEMBL30867763 | 0.71 | GPR119 (0.36) | MAP4K4GPR119LMNANPSR1HDAC1 | |
| SCHEMBL16272011 | 0.70 | GPR119 (0.45) | GPR119POLB | |
| SCHEMBL31283409 | 0.70 | GRM1 (0.46) | — | |
| SCHEMBL30867816 | 0.70 | DDB1 (0.33) | GPR119LMNANPSR1PIK3CA | |
| SCHEMBL22550617 | 0.70 | NR1H2 (0.36) | MAP4K4LMNANPSR1CYP1A2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132143-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4598917-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | Amgen Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| WO-2024076674-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2024-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132143-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | KRAS, NRAS, HRAS | MAP4K4 2295/4885GPR119 2581/4885LMNA 1584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.